Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 8/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353002 | 0.95 | L3MBTL1 (0.49) | L3MBTL1HCAR2ATMGLAKMT2A | |
| SCHEMBL18355233 | 0.93 | HCAR2 (0.52) | L3MBTL1HCAR2ATMACHE | |
| SCHEMBL18354873 | 0.90 | ATM (0.50) | HCAR2ATMACHE | |
| SCHEMBL18355226 | 0.88 | HCAR2 (0.50) | L3MBTL1HCAR2ATMKMT2AACHE | |
| SCHEMBL18354875 | 0.87 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2ATMKMT2A | |
| SCHEMBL18353205 | 0.84 | ATM (0.55) | HCAR2ATMACHE | |
| SCHEMBL18355109 | 0.84 | HCAR2 (0.43) | L3MBTL1HCAR2ATMKMT2AACHE | |
| SCHEMBL18353059 | 0.83 | ATM (0.47) | HCAR2KEAP1NFE2L2ATMKMT2A | |
| SCHEMBL18354903 | 0.83 | ATM (0.53) | HCAR2ATMACHE | |
| SCHEMBL6253988 | 0.81 | TSHR (0.52) | L3MBTL1GLAKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | L3MBTL1 4164/4885HCAR2 290/4885KEAP1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.